{
    "info": {
        "nct_id": "NCT03381274",
        "official_title": "A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC",
        "inclusion_criteria": "1. Age ≥ 18\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n3. Weight ≥ 35 kg\n4. Diagnosed with histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFRm\n\n   * For Arm A (Oleclumab + Osimertinib arms): must have received 1 prior line of therapy with an EGFR tyrosine kinase inhibitor (TKI) and confirmed T790M negative\n   * For Arm B (Oleclumab + AZD4635 arms): must have received at least 2 but not more than 4 prior lines of therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 101 Years",
        "exclusion_criteria": "1. Receipt of an EGFR TKI within 14 days of the first dose of study treatment\n2. Receipt of any conventional or investigational anticancer therapy not otherwise specified within 21 days of the planned first dose\n3. Prior receipt of any investigational immunotherapy. Participants may have received agents that have local health authority approval for the disease indication\n4. Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.\n5. Participants with a history of venous thrombosis within the past 3 months\n6. Participants with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 6 months\n7. Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment\n8. Other invasive malignancy within 2 years\n9. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression\n10. Current or prior use of immunosuppressive medication within 14 days prior to the first dose\n\nAdditional Exclusion Criteria for Arm A\n\n1. Concurrent treatment (or inability to stop therapy) with medications or herbal supplements known to be potent inducers of cytochrome P (CYP) 3A4\n2. Participants has a history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD\n3. Participants requires continuous supplemental oxygen for any reason\n\nAdditional Exclusion Criteria for Arm B\n\n1. Herbal preparations/medications are not allowed throughout the study\n2. History of seizures excluding those that occurred due to previously untreated CNS metastasis",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "1. Age ≥ 18",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Weight ≥ 35 kg",
            "criterions": [
                {
                    "exact_snippets": "Weight ≥ 35 kg",
                    "criterion": "weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 35,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Diagnosed with histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFRm",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed",
                    "criterion": "NSCLC diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced/metastatic NSCLC",
                    "criterion": "NSCLC stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "NSCLC with EGFRm",
                    "criterion": "EGFR mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "EGFR mutated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For Arm A (Oleclumab + Osimertinib arms): must have received 1 prior line of therapy with an EGFR tyrosine kinase inhibitor (TKI) and confirmed T790M negative",
            "criterions": [
                {
                    "exact_snippets": "must have received 1 prior line of therapy with an EGFR tyrosine kinase inhibitor (TKI)",
                    "criterion": "prior therapy with EGFR tyrosine kinase inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "line"
                            }
                        },
                        {
                            "requirement_type": "drug type",
                            "expected_value": "EGFR tyrosine kinase inhibitor"
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed T790M negative",
                    "criterion": "T790M mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For Arm B (Oleclumab + AZD4635 arms): must have received at least 2 but not more than 4 prior lines of therapy.",
            "criterions": [
                {
                    "exact_snippets": "must have received at least 2 but not more than 4 prior lines of therapy",
                    "criterion": "number of prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 101 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 101 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 101,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "10. Current or prior use of immunosuppressive medication within 14 days prior to the first dose",
            "criterions": [
                {
                    "exact_snippets": "Current or prior use of immunosuppressive medication within 14 days prior to the first dose",
                    "criterion": "immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "use within 14 days prior to first dose",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment",
            "criterions": [
                {
                    "exact_snippets": "Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment",
                    "criterion": "autoimmune or inflammatory disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participants requires continuous supplemental oxygen for any reason",
            "criterions": [
                {
                    "exact_snippets": "requires continuous supplemental oxygen for any reason",
                    "criterion": "supplemental oxygen requirement",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "continuous"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression",
            "criterions": [
                {
                    "exact_snippets": "Untreated central nervous system (CNS) metastatic disease",
                    "criterion": "central nervous system (CNS) metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cord compression",
                    "criterion": "cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Participants with a history of venous thrombosis within the past 3 months",
            "criterions": [
                {
                    "exact_snippets": "history of venous thrombosis within the past 3 months",
                    "criterion": "venous thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Concurrent treatment (or inability to stop therapy) with medications or herbal supplements known to be potent inducers of cytochrome P (CYP) 3A4",
            "criterions": [
                {
                    "exact_snippets": "Concurrent treatment ... with medications or herbal supplements known to be potent inducers of cytochrome P (CYP) 3A4",
                    "criterion": "concurrent treatment with CYP3A4 inducers",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to stop therapy ... with medications or herbal supplements known to be potent inducers of cytochrome P (CYP) 3A4",
                    "criterion": "inability to stop therapy with CYP3A4 inducers",
                    "requirements": [
                        {
                            "requirement_type": "ability to stop therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. History of seizures excluding those that occurred due to previously untreated CNS metastasis",
            "criterions": [
                {
                    "exact_snippets": "History of seizures excluding those that occurred due to previously untreated CNS metastasis",
                    "criterion": "history of seizures",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause exclusion",
                            "expected_value": "excluding those that occurred due to previously untreated CNS metastasis"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.",
            "criterions": [
                {
                    "exact_snippets": "Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.",
                    "criterion": "enrollment in another clinical study",
                    "requirements": [
                        {
                            "requirement_type": "type of study",
                            "expected_value": "therapeutic"
                        },
                        {
                            "requirement_type": "concurrent enrollment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Herbal preparations/medications are not allowed throughout the study",
            "criterions": [
                {
                    "exact_snippets": "Herbal preparations/medications are not allowed throughout the study",
                    "criterion": "herbal preparations/medications",
                    "requirements": [
                        {
                            "requirement_type": "use during study",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Receipt of any conventional or investigational anticancer therapy not otherwise specified within 21 days of the planned first dose",
            "criterions": [
                {
                    "exact_snippets": "Receipt of any conventional or investigational anticancer therapy ... within 21 days of the planned first dose",
                    "criterion": "anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Other invasive malignancy within 2 years",
            "criterions": [
                {
                    "exact_snippets": "Other invasive malignancy within 2 years",
                    "criterion": "other invasive malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Prior receipt of any investigational immunotherapy. Participants may have received agents that have local health authority approval for the disease indication",
            "criterions": [
                {
                    "exact_snippets": "Prior receipt of any investigational immunotherapy",
                    "criterion": "investigational immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants may have received agents that have local health authority approval for the disease indication",
                    "criterion": "agents with local health authority approval for the disease indication",
                    "requirements": [
                        {
                            "requirement_type": "prior receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participants has a history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD",
            "criterions": [
                {
                    "exact_snippets": "history of interstitial lung disease (ILD)",
                    "criterion": "interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "drug-induced ILD",
                    "criterion": "drug-induced interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation pneumonitis that required steroid treatment",
                    "criterion": "radiation pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "steroid treatment required",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any evidence of clinically active ILD",
                    "criterion": "clinically active interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Receipt of an EGFR TKI within 14 days of the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Receipt of an EGFR TKI within 14 days of the first dose of study treatment",
                    "criterion": "EGFR TKI receipt",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "6. Participants with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 6 months",
            "criterions": [
                {
                    "exact_snippets": "prior history of myocardial infarction ... in the last 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of transient ischemic attack ... in the last 6 months",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of ... stroke in the last 6 months",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Additional Exclusion Criteria for Arm B",
            "criterions": []
        },
        {
            "line": "Additional Exclusion Criteria for Arm A",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}